| DCC2485 |
Hatric |
Precursor for HATRIC-based ligand receptor capture (HATRIC-LRC) |
|
| DCC2486 |
Hbf-0079 |
Hepatocellular carcinoma (HCC)-selective cytotoxin, suppressing AKT anti-apoptotic signaling |
|
| DCC2487 |
Hc102a |
Novel Inhibitor of Mycobacterium tuberculosis DosRST signaling and persistence |
|
| DCC2488 |
Hc103a |
Novel Inhibitor of Mycobacterium tuberculosis DosRST signaling and persistence |
|
| DCC2489 |
Hc104a |
Novel inhibitor of DosRST, inhibiting DosR DNA binding in a dose-dependent manner by directly targeting DosR |
|
| DCC2490 |
Hc106a |
Novel inhibitor of DosRST, inhibiting Mtb survival during hypoxia-induced NRP, directly targeting the sensor kinase heme, via a mechanism that is distinct from the oxidation and alkylation of heme previously observed with artemisinin (HC101A) |
|
| DCC2491 |
Hca Xii-in-2c |
Novel inhibitor of human carbonic anhydrase XII (hCA-XII), demonstrating significant antiproliferative activity against hypoxic tumor cell lines |
|
| DCC2492 |
Hca-ix/xii-in-4m |
Novel selective dual carbonic anhydrase IX and XII inhibitor |
|
| DCC2493 |
Hci-2184 |
Novel Nek2 inhibitor, successfully mitigating drug resistance in bortezomib-resistant multiple myeloma; Potent AXL kinase inhibitor |
|
| DCC2494 |
Hcov-in-8n |
Novel inhibitor of human coronavirus 229E (hCoV 229E) replication with an EC50 value of 5.5 µM |
|
| DCC2495 |
HCT1026 |
Selective modulator of amyloid-beta peptide degradation, regulating Abeta levels. |
|
| DCC2496 |
Hct-13 |
Novel copper-dependent cytotoxic agent, being highly potent against a panel of pancreatic, small cell lung carcinoma, prostate cancer, and leukemia models, with IC50 values in the low-to-mid nanomolar range |
|
| DCC2497 |
Hcv Gt2a Inhibitor 5m |
Antiviral agent against HCV genotype 2a JFH-1 infected in human Huh7.5.1 cells |
|
| DCC2498 |
Hcv-in-5 |
Novel Inhibitor of Hepatitis C Virus |
|
| DCC2499 |
Hd-800 |
High affinity and selective colchicine site tubuline inhibitor amenable to radiolabel with C-11, a positron emitting isotope |
|
| DCC2500 |
Hdac6 Degrader 14a |
Novel PROTAC HDAC6 degrader, efficiently and selectively decreased HDAC6 levels in several cell lines, including activated THP-1 cells |
|
| DCC2501 |
Hdac6 Degrader Np8 |
Novel potent and selective PROTAC degrader of HDAC6 protein |
|
| DCC2502 |
Hdac6 Inhibitor 6h |
Novel hHDAC6 inhibitor, having low inhibitory potency over hHDAC1 and hHDAC8, as potential pharmacological tools for idiopathic pulmonary fibrosis (IPF) treatment |
|
| DCC2503 |
Hdac6 Inhibitor Xp5 |
Novel potent HDAC6 inhibitor with an IC 50 of 31 nM and excellent HDAC6 selectivity (SI = 338 for HDAC6 over HDAC3), displaying high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC |
|
| DCC2504 |
Hdac6-in-10c |
Novel HDAC6 isoform-selective inhibitor, increasing the acetylation level of α-tubulin with little effect on the acetylation of histone H3, inducing apoptosis in HL-60 cell by activating caspase 3 |
|
| DCC2505 |
Hdac6-in-3f |
Potent and selective HDAC6 inhibitor |
|
| DCC2506 |
Hdac6-in-4b |
Potent and selective HDAC6 inhibitor |
|
| DCC2507 |
Hdac6-in-w5 |
Novel highly potent and selective HDAC6 inhibitor with an IC 50 of 2.54 nM and being more than 290- to 3300-fold selective over other HDAC isoforms |
|
| DCC2508 |
Hdac8 Protac |
First-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8) |
|
| DCC2509 |
Hdac8-in-8b |
Novel Selective Histone Deacetylase 8 (HDAC8) Inhibitor with Anti-Neuroblastoma Activity |
|
| DCC2510 |
Hdac-in-6 |
Novel HDAC inhibitor, targeting HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9 |
|
| DCC2511 |
Hdac-in-h13 |
Novel Histone deacetylase (HDAC) inhibotor, displays potent inhibitory activity towards human HDACs and several cancer cells lines |
|
| DCC2512 |
Hdl376
Featured
|
HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease. |
|
| DCC2513 |
Hdp-mimic C4 |
Potent antifungal agent, hosting defense peptide mimic through a membrane-active mechanism |
|
| DCC2514 |
Hds029 |
Potent inhibitor of the ErbB receptor family (IC50 values are 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2 respectively) |
|
